Markets

Atara Biotherapeutics' Pierre Fabre Pharmaceuticals Partner Refiles Tabelecleucel Biologics License Application With FDA

Sep 30, 2026 · 08:09 AM ET· updated 1h ago

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and

Why It Matters

Atara's partner is trying again to get their medicine approved by the FDA. This shows the company is still working hard to bring their treatment to patients.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ATRA8.18

+0.13 (+1.65%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.